BioVaxys Technology Corp. (BVAXF) Stock Analysis
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
BioVaxys Technology Corp. (BVAXF) trades at $0.11 with AI Score 46/100 (Grade C). BioVaxys Technology Corp. (BVAXF) is a clinical-stage biotechnology company focused on developing innovative vaccines for antiviral diseases and cancer. Market cap: $3.21M, Sector: Healthcare.
Price as of Jul 23, 2026 · Last analyzed: Jun 15, 2026Analyst Coverage for BVAXF: BVAXF does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates BVAXF against Healthcare peers across nine fundamental dimensions and assigns an underweight signal based on the underlying data.
BVAXF: the 3 scored disciplines are evenly split. Dominant signal: Ray Dalio bullish.
How is this calculated? →Why this analysis is different
- A 9-signal quantitative MoonshotScore built from filings, insider activity, and market data — computed from the numbers, not from opinion.
- An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
- Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.
BioVaxys Technology Corp. (BVAXF) Healthcare & Pipeline Overview
BioVaxys Technology Corp. (BVAXF) specializes in developing cutting-edge vaccine platforms aimed at combating antiviral diseases and cancer, leveraging strategic collaborations to enhance its clinical pipeline and market reach.
What Is the Investment Thesis for BVAXF?
BioVaxys Technology Corp. (BVAXF) presents a unique investment thesis driven by its innovative vaccine pipeline and strategic collaborations. The company is advancing several promising candidates, including BVX-0320 and BVX-0918A, which target significant unmet medical needs in the antiviral and oncology spaces. The global vaccine market is projected to reach $100 billion by 2025, with an increasing demand for cancer immunotherapies, creating a favorable environment for BioVaxys's growth. Key value drivers include successful clinical trial outcomes, partnerships that enhance product development capabilities, and the potential for regulatory approvals that could lead to commercialization. However, inherent risks include the lengthy timelines associated with biotechnology product development and the potential for regulatory hurdles. Investors should monitor the progress of clinical trials and the company's funding requirements as it navigates the complexities of bringing novel therapeutics to market.
Based on FMP financials and quantitative analysis
BVAXF Key Highlights
- Market Cap: $0.00B, indicating a nascent stage in its market presence.
- Beta: 1.13, suggesting volatility in stock performance relative to the market.
- No dividend yield, reflecting reinvestment in research and development.
- Employee count of 3, indicating a lean operational structure.
- Focus on innovative vaccine platforms with multiple candidates in development.
Who Are BVAXF's Competitors?
BVAXF is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| MRNA Moderna, Inc. | $58.07 | -2.67% | $23.0B | — |
| BNTX BioNTech SE | $92.06 | +0.25% | $23.3B | 59 |
| PFE Pfizer Inc. | $25.01 | +0.77% | $143B | 65 |
| JNJ Johnson & Johnson | $259.27 | +1.42% | $624B | 96 |
| NVAX Novavax, Inc. | $7.83 | -0.95% | $1.29B | — |
| ADAPY Adaptimmune Therapeutics plc | $0.03 | +0.35% | $7.58M | 72 |
| BLRX BioLineRx Ltd. | $2.86 | +0.41% | $12.4M | 69 |
| GBIO Generation Bio Co. | $5.34 | +0.00% | $36.0M | 69 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are BVAXF's Key Strengths?
- Innovative vaccine candidates with potential to address significant health challenges.
- Strategic partnerships that enhance research and manufacturing capabilities.
- Focused expertise in both antiviral and oncology vaccine development.
- Lean operational structure enabling agile responses to market changes.
What Are BVAXF's Weaknesses?
- Limited financial resources due to small market capitalization.
- High dependency on successful clinical trial outcomes for future growth.
- Small employee base may limit operational capacity and scalability.
- Lack of established market presence compared to larger competitors.
What Could Drive BVAXF Stock Higher?
- Clinical trial results for BVX-0320 expected within the next 12-18 months.
- Development of BVX-0918A and BVX-0918C vaccines for ovarian and cervical cancers.
- Strategic collaborations enhancing research and development capabilities.
- Potential regulatory submissions for vaccine candidates as trials progress.
- Expansion of immunodiagnostic tool offerings with CoviDTH.
What Are the Key Risks for BVAXF?
- Weak fundamentals — a Piotroski F-Score of 1/9 flags soft profitability, leverage or efficiency.
- High dependency on successful clinical trial outcomes for future growth.
- Intense competition from established players in the biotechnology sector.
- Regulatory challenges that may delay product approvals.
- Market volatility affecting funding and operational stability.
- Limited financial resources impacting research and development capabilities.
What Are the Growth Opportunities for BVAXF?
- Growth opportunity 1: BioVaxys is advancing its BVX-0320 vaccine, which targets SARS-CoV-2 and is part of a growing global vaccine market projected to reach $100 billion by 2025. With increasing vaccination rates and potential booster requirements, BVX-0320 could capture significant market share if clinical trials yield positive results, expected in the next 12-18 months.
- Growth opportunity 2: The oncology segment represents a substantial growth avenue for BioVaxys, particularly with its BVX-0918A and BVX-0918C vaccines targeting ovarian and cervical cancers, respectively. The global cancer vaccine market is projected to grow at a CAGR of 14.5%, reaching $7.5 billion by 2026, providing a lucrative opportunity for BioVaxys if it successfully navigates clinical trials.
- Growth opportunity 3: BioVaxys's focus on HPV-related therapies, including the BVX-0204 vaccine, addresses a significant public health concern, as HPV is linked to various cancers. The HPV vaccine market is expected to expand, driven by increasing awareness and vaccination initiatives, which could position BioVaxys favorably within this sector.
- Growth opportunity 4: The CoviDTH immunodiagnostic tool offers a unique value proposition in the post-COVID-19 landscape, where understanding immune responses is critical. The market for immunodiagnostic tools is expected to grow, providing BioVaxys an opportunity to leverage its technology for broader applications beyond SARS-CoV-2.
- Growth opportunity 5: Strategic collaborations with institutions like The Ohio State University and WuXi Biologics enhance BioVaxys's research capabilities and manufacturing efficiencies. These partnerships can accelerate product development timelines and reduce costs, positioning the company for faster market entry as it seeks to commercialize its vaccine candidates.
What Opportunities Does BVAXF Have?
- Growing global vaccine market presents significant revenue potential.
- Increasing demand for cancer immunotherapies provides a favorable environment.
- Potential for expansion into new therapeutic areas beyond current pipeline.
- Strategic collaborations can lead to enhanced product development and commercialization.
What Threats Does BVAXF Face?
- Intense competition from established biotechnology and pharmaceutical companies.
- Regulatory challenges that may delay product approvals and market entry.
- Market volatility and economic downturns affecting funding opportunities.
- Uncertainty in clinical trial outcomes impacting investor confidence.
What Are BVAXF's Competitive Advantages?
- Innovative haptenized cell platform technology differentiates BioVaxys from competitors.
- Strategic collaborations enhance research capabilities and reduce development risks.
- Focus on high unmet medical needs in oncology and infectious diseases provides a competitive edge.
- Early-stage promise of vaccine candidates could lead to significant market opportunities.
- Lean operational structure allows for agile decision-making and resource allocation.
What Does BVAXF Do?
BioVaxys Technology Corp. (BVAXF) is a clinical-stage biotechnology company headquartered in Etobicoke, Canada, dedicated to the development of innovative vaccine platforms targeting both antiviral diseases and various forms of cancer. Founded with the vision of creating effective therapeutic solutions, BioVaxys has evolved to focus on a robust pipeline that includes two SARS-CoV-2 vaccines: BVX-0320, a monovalent candidate, and BVX-0121, a multivalent option. In addition to its antiviral efforts, the company is advancing its oncology initiatives, which feature BVX-0918A, a haptenized tumor cell vaccine for ovarian cancer, and BVX-0918C, designed for cervical cancer. BioVaxys also addresses Human Papillomavirus (HPV) through programs like Papilocare for HPV-dependent cervical lesions and the BVX-0204 HPV viral vaccine. Furthermore, the company offers CoviDTH, an immunodiagnostic tool that detects immune responses in individuals exposed to SARS-CoV-2. To bolster its development initiatives, BioVaxys has established strategic collaborations, including a bioproduction agreement with WuXi Biologics Limited for the manufacturing of SARS-CoV-2 s-proteins, vital for its vaccine candidates. Additionally, it collaborates with The Ohio State University, Wexner School of Medicine, for research on BVX-0320, and has engaged Bioanalytical Systems, Inc. for preclinical toxicology studies on CoviDTH. With a small team of three employees, BioVaxys is positioned as a nimble player in the biotechnology sector, focusing on high-impact therapeutic solutions.
What Products and Services Does BVAXF Offer?
- Develop innovative vaccine platforms targeting antiviral diseases and cancer.
- Advance multiple vaccine candidates, including those for SARS-CoV-2 and HPV.
- Conduct clinical trials to evaluate the safety and efficacy of its products.
- Establish strategic collaborations to enhance research and development capabilities.
- Offer immunodiagnostic tools to detect immune responses to viral infections.
- Focus on addressing significant unmet medical needs in oncology and infectious diseases.
How Does BVAXF Make Money?
- Generate revenue through the development and potential commercialization of vaccine candidates.
- Engage in partnerships and collaborations to share research costs and expertise.
- Leverage grants and funding opportunities to support clinical trials and product development.
- Utilize licensing agreements for technology and product distribution.
- Focus on innovative solutions that address critical health challenges in the market.
What Industry Does BVAXF Operate In?
The biotechnology industry is characterized by rapid advancements in drug development, particularly in the vaccine sector, which has gained prominence due to the COVID-19 pandemic. The global biotechnology market is expected to grow at a CAGR of 7.4%, reaching approximately $2.4 trillion by 2028. BioVaxys Technology Corp. operates within this dynamic landscape, focusing on both antiviral and oncology vaccine development. The competitive landscape includes established players and emerging biotech firms, with a trend towards personalized medicine and immunotherapy. BioVaxys's innovative approach and strategic collaborations position it well to capitalize on these industry trends.
Who Are BVAXF's Key Customers?
- Healthcare providers looking for innovative vaccine solutions.
- Patients in need of effective cancer therapies and antiviral vaccines.
- Research institutions collaborating on vaccine development.
- Public health organizations addressing infectious disease outbreaks.
- Pharmaceutical companies seeking partnerships for vaccine commercialization.
ROE 122%Key Financial Metrics
Return on equity for BioVaxys Technology Corp. stands at 121.9%, a gauge of how efficiently it converts shareholder capital into profit. Its free cash flow yield is -95.9%, a gauge of the cash the business throws off relative to its market value. A current ratio of 0.28 means current liabilities exceed short-term assets, a liquidity point worth watching. Its earnings yield is -161.6%, the inverse of the P/E and a quick read on earnings relative to price.
How BioVaxys Technology Corp. Is Valued
BioVaxys Technology Corp. carries a market capitalization of $3.21M, placing it in the micro-cap category. Relative to its peer group, BVAXF's quantitative score of 46/100 is below the peer average of 73/100.
F-Score 1/9Financial Health
BioVaxys Technology Corp.'s Piotroski F-Score is 1/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny.
BVAXF Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis · FY 2024
Bull Case vs Bear Case
Bull Case
- BioVaxys' cancer vaccine platform is generating considerable buzz within the biotech community, suggesting potential for groundbreaking advancements.
- Recent insider buying activity signals confidence from within the company, often a positive indicator for future performance.
- The company's focus on both cancer and viral vaccines positions it to capitalize on multiple market opportunities.
- Social sentiment indicates growing excitement around upcoming clinical trial results, potentially driving increased investor interest.
Bear Case
- Biotech ventures, especially in early stages, carry significant risk of clinical trial failure, which could severely impact the stock.
- The community is wary of penny stocks, and BVAXF's volatility could lead to substantial losses for inexperienced investors.
- Competition in the cancer vaccine space is fierce, with larger, more established players posing a significant challenge.
- Negative chatter online suggests some investors are concerned about potential dilution due to the company's financing needs.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · April 2026
BVAXF Latest News
No recent news available for BVAXF.
BVAXF Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for BVAXF.
Price Targets
Wall Street price target analysis for BVAXF.
BVAXF MoonshotScore
What does this score mean?
The MoonshotScore rates BVAXF 0-100 on quantitative fundamentals — growth, financial health, valuation, momentum, and risk.
Leadership: James Christopher Passin
CEO
James Christopher Passin has a diverse background in finance and biotechnology, with a focus on strategic management and operational excellence. He has held various leadership roles in the biotech sector, where he has successfully guided companies through critical growth phases. His educational background includes degrees in finance and life sciences, equipping him with a unique perspective on the intersection of business and healthcare.
Track Record: Under James Christopher Passin's leadership, BioVaxys has advanced its clinical pipeline significantly, establishing key collaborations that enhance its research capabilities. His strategic vision has positioned the company to address critical health challenges through innovative vaccine development.
BVAXF OTC Market Information
The OTC Other tier includes companies that do not meet the financial standards for the higher OTC tiers or major exchanges. This tier often features smaller companies with limited trading volumes, which may result in less liquidity and higher volatility compared to stocks listed on NYSE or NASDAQ.
- OTC Tier: OTC Other
- Limited financial resources and market presence may affect operational stability.
- Higher volatility and lower liquidity compared to stocks on major exchanges.
- Potential regulatory scrutiny due to lack of comprehensive disclosures.
- Market perception risks associated with being an OTC-listed company.
- Review the company's clinical trial progress and results.
- Assess the strength and terms of strategic collaborations.
- Evaluate financial health and funding strategies.
- Monitor market trends in the biotechnology and vaccine sectors.
- Investigate the company's intellectual property portfolio.
- Established collaborations with reputable institutions like The Ohio State University.
- Engagement in preclinical studies with Bioanalytical Systems, Inc.
- Focus on addressing significant health challenges through innovative solutions.
What Investors Ask About BioVaxys Technology Corp. (BVAXF) — Healthcare
What does the AI Score mean for BVAXF?
BVAXF holds an AI Score of 46/100 (Grade: C). This is an educational research signal, not a buy or sell recommendation. BioVaxys Technology Corp. (BVAXF) is a clinical-stage biotechnology company focused on developing innovative vaccines for antiviral diseases and cancer. The company is advancing a diverse pipeline …
What does BioVaxys Technology Corp. do?
BioVaxys Technology Corp. specializes in developing innovative vaccine platforms aimed at combating antiviral diseases and various forms of cancer. The company is advancing multiple candidates, including vaccines for SARS-CoV-2 and HPV, alongside immunodiagnostic tools to assess immune responses.
What are the main risks for BVAXF?
The main risks for BioVaxys Technology Corp. include high dependency on successful clinical trial outcomes, which are crucial for future growth. Additionally, the company faces intense competition from established biotechnology firms, regulatory challenges that may delay product approvals, and market volatility that could impact funding opportunities.
What is BioVaxys Technology Corp.'s drug pipeline status?
BioVaxys Technology Corp. is advancing a diverse drug pipeline, including BVX-0320 and BVX-0121 for SARS-CoV-2, and BVX-0918A and BVX-0918C targeting ovarian and cervical cancers, respectively. The company is actively conducting clinical trials and collaborating with research institutions to enhance its development efforts.
What are the key factors to evaluate for BVAXF?
BioVaxys Technology Corp. (BVAXF) holds an AI score of 46/100 (low). Not financial advice.
How frequently does BVAXF data refresh on this page?
BVAXF's price was last updated on Jul 23, 2026 and refreshes on page view during U.S. market hours — it is not a real-time exchange feed. Fundamentals update after quarterly filings; the MoonshotScore recalculates nightly; news aggregates continuously.
What has driven BVAXF's recent stock price performance?
BioVaxys Technology Corp. (BVAXF) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Innovative vaccine candidates with potential to address significant health challenges. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider BVAXF overvalued or undervalued right now?
BioVaxys Technology Corp. (BVAXF) has no trailing P/E available here, so lean on price-to-sales and cash flow in the Financials tab. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
How do I research BVAXF before investing?
Before investing in BioVaxys Technology Corp. (BVAXF), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) analyst consensus ratings and price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Financial reports and disclosures are limited due to OTC classification.